Adverse Effects of Collagenase in the Treatment of Dupuytren Disease: A Systematic Review
- 8 February 2017
- journal article
- research article
- Published by Springer Nature in BioDrugs
- Vol. 31 (2) , 105-115
Abstract
Collagenase clostridium histolyticum (CCH) has proven to be both safe and effective in the treatment of Dupuytren disease (DD). The medium-term outcomes are similar to those achieved with surgery, and most adverse effects are self-limiting and considered to be mild or moderate.Keywords
This publication has 46 references indexed in Scilit:
- Surgical findings in the treatment of Dupuytren’s disease after initial treatment with clostridial collagenase (Xiaflex)Journal of Hand Surgery (European Volume), 2013
- Skin Graft Loss Resulting From Collagenase Clostridium Histolyticum Treatment of Dupuytren Contracture: Case Report and Review of the LiteratureThe Journal of Hand Surgery, 2013
- Efficacy and Safety of Collagenase Clostridium Histolyticum Injection for Dupuytren Contracture: Short-Term Results From 2 Open-Label StudiesThe Journal of Hand Surgery, 2013
- Late Complications of Clinical Clostridium Histolyticum Collagenase Use in Dupuytren's DiseasePLOS ONE, 2012
- Multiple concurrent collagenase clostridium histolyticum injections to dupuytren’s cords: an exploratory studyBMC Musculoskeletal Disorders, 2012
- Nonsurgical Treatment of Dupuytren's Contracture: 1-Year US Post-Marketing Safety Data for Collagenase Clostridium HistolyticumHAND, 2012
- The Wound Healing Process: An Overview of the Cellular and Molecular MechanismsJournal of International Medical Research, 2009
- Proposed New Diagnostic Criteria for Complex Regional Pain SyndromePain Medicine, 2007
- Collagen-derived peptides release mast cell histamineInflammation Research, 1986
- Relationship between the individual collagenases of Clostridium histolyticum: evidence for evolution by gene duplicationBiochemistry, 1984